China's Innovent jumps as phase 3 clinical trial of obesity drug meets endpoints

China Renaissance Holdings

09/01/2024 07:49

** Shares of China's biopharmaceutical group Innovent
Biologics Inc  1801.HK  jump as much as 5.9% to HK$40.55; on
course to snap two consecutive sessions of fall  
    ** Stock on track for the biggest one-day pct rise since
Dec. 27, if gains hold
    ** Innovent says the first Phase 3 clinical trial of its
mazdutide drug in Chinese adults with overweight or obesity met
the primary and all key secondary endpoints
    ** Hong Kong's healthcare index  .HSCIH  rises 2%, while
Hang Seng Composite Index  .HSCI  and Hang Seng Index  .HIS 
both add 0.1%


 (Reporting by Donny Kwok)
 ((donny.kwok@thomsonreuters.com))